The Hidden Rise in Toxic Air Pollution during the COVID-19 Pandemic: is our response worsening the respiratory burden of particulate matter in the UK?

Project Details

Description

Air pollution is arguably the single biggest threat facing global health today and increasing evidence indicates the most harmful pollutants are ultrafine particles (UFPs). UFP are believed to be more toxic to the human body than other species of air pollution currently covered by law, yet are neither routinely monitored or legislated for.

Recent research has highlighted the concerning paradigm that reducing ambient concentrations of legislated air pollution, in the form of PM2.5, may lead to a decline in air quality by increasing the concentration of more harmful ultrafine particles (UFP; diameter ≤100nm).

It has been shown that PM2.5 plays a crucial role in suppression of UFP numbers, with larger PM2.5 particles acting to scavenge the more toxic UFP from the air. Consequently, removal of PM2.5 as a UFP sink may result in enhanced ambient UFP numbers, particularly if UFP emissions and gaseous precursor concentrations remain unchecked. With the outbreak of the COVID-19 pandemic, anthropogenic activity around the globe has decreased in a vast and unprecedented manner, to such an extent that concentrations of commonly measured primary air pollutants have decreased dramatically.

However, levels of secondary pollutants (which often correlate with finest UFP fractions) have already begun to rise. It follows that this sudden, global drop in anthropogenic activity and ambient PM2.5 has the potential to drive an unexpected and potentially significant increase in UFP concentrations and associated detrimental health effects.

If we are now inadvertently adding an unlooked-for cardio-respiratory pollutant into the air at a time when many are vulnerable to a virus that impacts the respiratory system, we risk widening the COVID-19 ‘window of vulnerability’, where increased UFP exposure acts to exacerbate underlying conditions for individuals with pre-existing comorbidities, who may otherwise be considered ‘lower risk’, and worsen the impact of the virus for those already considered as ‘at risk’.
AcronymHRITAP
StatusActive
Effective start/end date1/06/2031/05/21

Funding

  • UKRI

Keywords

  • PRP EXEMPTION